To include your compound in the COVID-19 Resource Center, submit it here.

Galectin's NASH candidate misses in Phase IIb

Galectin Therapeutics Inc. (NASDAQ:GALT) said galactoarabino-rhamnogalacturonate (GR-MD-02) missed the primary endpoint of reducing hepatic venous pressure gradient (HVPG) in the double-blind, U.S. Phase IIb NASH-CX trial to treat patients

Read the full 298 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE